Reporting of long-term extension studies: lack of consistency calls for consensus
- 6 March 2011
- journal article
- viewpoint
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 70 (6), 886-890
- https://doi.org/10.1136/ard.2010.143420
Abstract
Double-blind, randomised controlled studies represent the gold-standard approach to determine the safety and efficacy of therapeutic interventions. In chronic conditions such as rheumatoid arthritis (RA), long-term data are vital to confirm maintenance of effect and identify potential safety signals. The recent introduction of numerous biological therapies for RA has been followed by various long-term extension (LTE) studies. Although useful, the design and method of analysis in such studies vary significantly, partly due to their complexity. This viewpoint highlights general considerations needed when undertaking a LTE study and illustrates the lack of consistency in studies of RA to date. It addresses issues of selection bias, patient discontinuation and missing data. Although used for safety reporting, the lack of adequate powering makes LTE studies of limited benefit. Ethical considerations and challenges are highlighted, including potential conflicts of interest. Finally, the authors suggest the need for consensus to ensure more reliable interpretation and application of data for clinical practice. Following the development of guidelines on reporting of clinical trials in RA and more recently, registry data, a similar approach for LTE studies would be a useful endeavour.Keywords
This publication has 23 references indexed in Scilit:
- Treating rheumatoid arthritis to target: recommendations of an international task forceAnnals Of The Rheumatic Diseases, 2010
- Familial influence on tibiofemoral alignmentAnnals Of The Rheumatic Diseases, 2009
- Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION studyAnnals Of The Rheumatic Diseases, 2009
- Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension studyAnnals Of The Rheumatic Diseases, 2008
- Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendationsAnnals Of The Rheumatic Diseases, 2008
- Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trialThe Lancet, 2008
- Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeksArthritis & Rheumatism, 2006
- Sustained benefit in rheumatoid arthritis following one course of rituximab: improvements in physical function over 2 yearsRheumatology, 2006
- Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended studyAnnals Of The Rheumatic Diseases, 2006
- Long‐term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin‐1 receptor antagonist) in patients with rheumatoid arthritis: Extension phase of a randomized, double‐blind, placebo‐controlled trialArthritis & Rheumatism, 2002